• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

<编辑精选> 联合治疗对日本特发性或遗传性肺动脉高压患者风险分层表各项指标的影响差异。

<Editors' Choice> Differential effects of combination therapy on the components of the risk stratification table in patients with idiopathic or heritable pulmonary arterial hypertension in a Japanese population.

机构信息

Department of Cardiology, Nagoya University Hospital, Nagoya, Japan.

Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

出版信息

Nagoya J Med Sci. 2021 May;83(2):321-330. doi: 10.18999/nagjms.83.2.321.

DOI:10.18999/nagjms.83.2.321
PMID:34239180
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8236678/
Abstract

Risk stratification by ESC/ERS guideline is recommended to estimate the vital prognosis and select the treatment strategy in patients with idiopathic or heritable pulmonary arterial hypertension (IPAH/HPAH). However, we are not confident whether we can achieve low-risk status in the risk table at the follow-up shortly after combination therapy. Therefore, we aimed to verify the effects of combination therapy in IPAH/HPAH on each category of the risk table at diagnosis and at the first follow-up. We retrospectively analyzed 10 consecutive patients with IPAH/HPAH with no previous treatment history diagnosed at Nagoya University Hospital between October 2014 and January 2019. Four categories including symptoms, exercise tolerance, BNP levels and hemodynamics were validated both at baseline and at the first follow-up of right heart catheterization. Score of 1, 2 and 3 were assigned to the low risk, intermediate risk and high risk, respectively. In each category the highest score was adopted. The scores at diagnosis were compared with those at the first follow-up. The result shows that all patients were female, median age was 32 years old, and were treated with initial combination therapy. The median total risk score also was improved from 2.6 to 1.4 (p<0.01). However, the score in exercise tolerance was not improved (3 to 2.5 p=0.16). In conclusion, at the first follow up shortly after the initial combination therapy of IPAH/HPAH, the mean total risk score was significantly improved, however, even patients in the low-risk status may not achieve improvement in exercise tolerance.

摘要

风险分层推荐采用 ESC/ERS 指南,以估计特发性或遗传性肺动脉高压(IPAH/HPAH)患者的重要预后并选择治疗策略。然而,我们不确定在联合治疗后不久的随访中是否能够达到风险表中的低危状态。因此,我们旨在验证 IPAH/HPAH 患者在诊断和首次随访时对风险表中每个类别的联合治疗效果。我们回顾性分析了 2014 年 10 月至 2019 年 1 月期间在名古屋大学医院诊断的 10 例无既往治疗史的 IPAH/HPAH 连续患者。在基线和首次右心导管检查的第一次随访中验证了包括症状、运动耐量、BNP 水平和血液动力学在内的四个类别的情况。低危、中危和高危分别赋值 1、2 和 3 分。每个类别采用最高评分。比较诊断时和第一次随访时的评分。结果显示,所有患者均为女性,中位年龄为 32 岁,接受初始联合治疗。中位总风险评分也从 2.6 改善至 1.4(p<0.01)。然而,运动耐量评分没有改善(3 分改善至 2.5 分,p=0.16)。总之,在 IPAH/HPAH 初始联合治疗后的首次随访中,总风险评分的平均值显著改善,但即使处于低危状态的患者,运动耐量也可能无法改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/c52364983a6b/2186-3326-83-0321-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/e1874031c685/2186-3326-83-0321-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/273c9e4f98bf/2186-3326-83-0321-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/1a64ad65f1f6/2186-3326-83-0321-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/f3fe9d81a3f6/2186-3326-83-0321-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/c52364983a6b/2186-3326-83-0321-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/e1874031c685/2186-3326-83-0321-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/273c9e4f98bf/2186-3326-83-0321-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/1a64ad65f1f6/2186-3326-83-0321-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/f3fe9d81a3f6/2186-3326-83-0321-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d2d/8236678/c52364983a6b/2186-3326-83-0321-g005.jpg

相似文献

1
<Editors' Choice> Differential effects of combination therapy on the components of the risk stratification table in patients with idiopathic or heritable pulmonary arterial hypertension in a Japanese population.<编辑精选> 联合治疗对日本特发性或遗传性肺动脉高压患者风险分层表各项指标的影响差异。
Nagoya J Med Sci. 2021 May;83(2):321-330. doi: 10.18999/nagjms.83.2.321.
2
Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.肺动脉高压的一线单药治疗和联合治疗的预后及反应
Scand Cardiovasc J. 2014 Aug;48(4):223-33. doi: 10.3109/14017431.2014.931595.
3
Missense mutations of the BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension.BMPR1B(ALK6)基因突变与儿童特发性肺动脉高压。
Circ J. 2012;76(6):1501-8. doi: 10.1253/circj.cj-11-1281. Epub 2012 Feb 25.
4
Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan.在日本一家单一中心接受治疗的特发性/遗传性肺动脉高压患者的长期生存情况。
Life Sci. 2014 Nov 24;118(2):414-9. doi: 10.1016/j.lfs.2014.01.077. Epub 2014 Feb 11.
5
[Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry].[根据俄罗斯登记处的数据,不可手术的慢性血栓栓塞性肺动脉高压和特发性肺动脉高压患者的临床、功能和血流动力学特征、药物治疗及预后评估]
Ter Arkh. 2019 Sep 15;91(9):77-87. doi: 10.26442/00403660.2019.09.000343.
6
Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.静脉注射依前列醇转换为口服/吸入靶向肺动脉高压治疗儿童特发性和家族性肺动脉高压的疗效。
Am J Cardiol. 2010 May 15;105(10):1485-9. doi: 10.1016/j.amjcard.2009.12.075. Epub 2010 Apr 8.
7
Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).先天性心脏病相关肺动脉高压患者的 4 年和 7 年结局(来自 REVEAL 登记研究)。
Am J Cardiol. 2014 Jan 1;113(1):147-55. doi: 10.1016/j.amjcard.2013.09.032. Epub 2013 Oct 4.
8
Outcomes of idiopathic pulmonary arterial hypertension in Japanese children: a retrospective cohort study.日本儿童特发性肺动脉高压的结局:一项回顾性队列研究。
Heart Vessels. 2021 Sep;36(9):1392-1399. doi: 10.1007/s00380-021-01806-1. Epub 2021 Mar 18.
9
EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension.诊断为肺动脉高压患者的EIF2AK4基因突变
Chest. 2017 Apr;151(4):821-828. doi: 10.1016/j.chest.2016.11.014. Epub 2016 Nov 22.
10
Elevated levels of plasma transforming growth factor-β1 in idiopathic and heritable pulmonary arterial hypertension.特发性和遗传性肺动脉高压患者血浆转化生长因子-β1水平升高。
Int J Cardiol. 2016 Nov 1;222:368-374. doi: 10.1016/j.ijcard.2016.07.192. Epub 2016 Jul 29.

引用本文的文献

1
Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review.连续风险分层对成人和儿科肺动脉高压的预后价值:系统评价。
J Am Heart Assoc. 2024 Jul 2;13(13):e034151. doi: 10.1161/JAHA.123.034151. Epub 2024 Jun 21.

本文引用的文献

1
<Editors' Choice> Pulmonary Hypertension: Diagnosis, Management, and Treatment.<编辑推荐> 肺动脉高压:诊断、管理与治疗
Nagoya J Med Sci. 2019 Feb;81(1):19-30. doi: 10.18999/nagjms.81.1.19.
2
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.肺动脉高压的风险评估、预后和指南实施。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00889-2017. Print 2017 Aug.
3
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.
肺动脉高压死亡率:2015 年欧洲肺动脉高压指南风险分层模型预测。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00740-2017. Print 2017 Aug.
4
Validation of a risk assessment instrument for pulmonary arterial hypertension.一种用于肺动脉高压的风险评估工具的验证
Eur Heart J. 2018 Dec 14;39(47):4182-4185. doi: 10.1093/eurheartj/ehx301.
5
Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension.日本特发性/遗传性肺动脉高压患者的生存情况
Am J Cardiol. 2017 May 1;119(9):1479-1484. doi: 10.1016/j.amjcard.2017.01.015. Epub 2017 Feb 9.
6
Effects of bosentan on peripheral endothelial function in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.波生坦对肺动脉高压或慢性血栓栓塞性肺动脉高压患者外周血管内皮功能的影响。
Pulm Circ. 2016 Jun;6(2):168-73. doi: 10.1086/685715.
7
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015年欧洲心脏病学会(ESC)/欧洲呼吸学会(ERS)肺动脉高压诊断和治疗指南:欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)肺动脉高压诊断和治疗联合工作组:得到以下组织认可:欧洲儿科和先天性心脏病协会(AEPC)、国际心肺移植学会(ISHLT)。
Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.
8
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015 ESC/ERS 肺动脉高压诊断与治疗指南:欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)肺动脉高压诊断与治疗工作组制定:该指南得到了欧洲儿科和先天性心脏病协会(AEPC)以及国际心肺移植学会(ISHLT)的认可。
Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29.
9
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.初始使用安贝生坦联合他达拉非治疗肺动脉高压。
N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.
10
Skeletal muscle abnormalities in pulmonary arterial hypertension.肺动脉高压中的骨骼肌异常。
PLoS One. 2014 Dec 2;9(12):e114101. doi: 10.1371/journal.pone.0114101. eCollection 2014.